Lexaria Bioscience Corp.
Lexaria Bioscience Corp.
Your view on LEXX
Overview
What the company does, where it operates, and who runs it.
About Lexaria Bioscience Corp.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard C. Christopher
- Headquarters
- 100 – 740 McCurdy Road, Kelowna, BC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard C. Christopher
- Headquarters
- 100 – 740 McCurdy Road, Kelowna, BC, CA
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery.
The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others.
DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Past Reports
Historical coverage archive.
*Lexaria Bioscience Corp. had paid FRC a fee for research coverage and distribution of reports. This fee creates a potential conflict of interest which readers should consider.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Lexaria Bioscience Corp. from FRC's valuation model, read against the market price. LEXX last traded at $4.64; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Lexaria Bioscience Corp.. Starting points for Lexaria Bioscience Corp.: EPS -$4.68, beta 0.34 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Lexaria Bioscience Corp.. Lexaria Bioscience Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Lexaria Bioscience Corp.. Trailing twelve-month EPS for Lexaria Bioscience Corp. stands at -$4.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$1.50
Median
$1.50
High
$1.50
Average target
Analyst Ratings
- Strong Buy0
- Buy2
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrAug 2026 | Next QtrNov 2026 | Current YearFY Aug 2026 | Next YearFY Aug 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.90 | -$4.35 | -$4.05 | -$4.65 |
| Low estimate | -$0.90 | -$4.35 | -$4.05 | -$4.65 |
| High estimate | -$0.90 | -$4.35 | -$4.05 | -$4.65 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$2.10 | -$1.12 | -$9.90 | — |
| Growth | +57.1% | -288.7% | +59.1% | — |
Revenue Estimate
| Revenue | Current QtrAug 2026 | Next QtrNov 2026 | Current YearFY Aug 2026 | Next YearFY Aug 2027 |
|---|---|---|---|---|
| Avg. estimate | $50000.00 | $0.00 | $20000.00 | $1.40M |
| Low estimate | $50000.00 | $0.00 | $20000.00 | $1.40M |
| High estimate | $50000.00 | $0.00 | $20000.00 | $1.40M |
| No. of analysts | 1 | 0 | 1 | 1 |
| Year-ago revenue | $174000.00 | $0.00 | $705923.00 | — |
| Growth | -71.3% | — | -97.2% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Lexaria Bioscience Corp.. Lexaria Bioscience Corp. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Lexaria Bioscience Corp. valued side by side against its closest peers. Lexaria Bioscience Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Lexaria Bioscience Corp., and how their positions are changing. At a $7.7M market value, institutional positions materially move Lexaria Bioscience Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Lexaria Bioscience Corp. executives and directors. Shares of Lexaria Bioscience Corp. have traded between $0.78 and $2.85 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Lexaria Bioscience Corp.. Coverage tracks Lexaria Bioscience Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Lexaria Bioscience Corp.